Table 2.

In vitro antimicrobial and anticancer screening of the synthesized derivatives (1–26)

Comp. no.	Antimicrobial screening (MIC = ×10−3 µM)							Anticancer screening (IC50 = µM)
	BS	PA	EC	ST	KP	AN	CA	HCT-116
1	2.83	2.83	2.83	2.83	2.83	5.66	0.34	192.5
2	2.65	2.65	5.30	5.30	5.30	5.30	0.66	84.8
3	2.65	2.65	2.65	2.65	2.65	2.65	0.66	> 212.1
4	2.49	4.98	2.49	4.98	2.49	2.49	0.62	39.9
5	2.49	4.98	4.98	2.49	2.49	4.98	1.25	> 199.4
6	1.18	4.70	2.35	2.35	4.70	4.70	0.59	24.5
7	2.58	5.17	2.58	5.17	5.17	5.17	0.65	> 206.8
8	2.45	4.91	4.91	4.91	4.91	4.91	0.61	> 196.3
9	2.68	5.36	5.36	5.36	5.36	2.68	0.67	> 214.4
10	1.14	4.57	2.28	4.57	4.57	4.57	0.57	> 182.6
11	1.28	5.14	5.14	5.14	5.14	5.14	0.64	> 205.5
12	2.57	5.14	5.14	5.14	2.57	5.14	1.28	> 205.5
13	2.57	2.57	5.14	5.14	1.28	5.14	0.64	> 205.5
14	2.63	2.63	2.63	5.25	1.31	5.25	0.66	> 210.1
15	2.63	5.25	5.25	2.63	1.31	5.25	1.31	> 210.1
16	1.22	4.90	2.45	4.90	1.22	4.90	1.22	> 195.9
17	2.52	5.05	2.52	2.52	1.26	2.52	0.63	> 201.8
18	2.72	5.44	2.72	2.72	1.36	5.44	5.44	78.3
19	2.40	4.80	4.80	2.40	4.80	2.40	4.80	> 192.2
20	2.40	4.80	4.80	2.40	4.80	4.80	4.80	> 192.2
21	2.60	5.20	2.60	2.60	5.20	2.60	5.20	> 208.1
22	2.67	2.67	5.35	5.35	5.35	5.35	5.35	70.6
23	2.82	5.65	1.41	2.82	5.65	5.65	5.65	> 226
24	2.79	5.59	1.40	2.79	2.79	2.79	2.79	96.1
25	2.71	5.42	2.71	2.71	5.42	2.71	2.71	45.5
26	2.73	2.73	2.73	2.73	5.46	5.46	5.46	35.6
Ofloxacin	1.73	3.46	3.46	1.73	3.46	–	–	–
Fluconazole	–	–	–	–	–	4.08	2.04	–
5-FU	–	–	–	–	–	–	–	29.2